Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAVE long-term durvalumab safety and efficacy follow-up
jRCT2080225003Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of durvalumab in Non-hematologic malignancy and hematopoietic malignancies (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Long-term safety of durvalumab and Long-term efficacy of durvalumab. Started Jan 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on jRCT2080225003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225003.